Liver Cancer Drugs Market
Report ID: SQMIG35B2174
Report ID:
SQMIG35B2174 |
Region:
Global |
Published Date: December, 2024
Pages:
157
|Tables:
114
|Figures:
67
Liver Cancer Drugs Market size was valued at USD 3.18 Billion in 2023 and is poised to grow from USD 3.74 Billion in 2024 to USD 13.64 Billion by 2032, growing at a CAGR of 17.6% during the forecast period (2025-2032).
The availability of novel drugs, the presence of strong pipelines, and rising public awareness are among the key trends escalating market growth. Besides this, growing incidence of liver cancer due to increasing geriatric population and unorganized lifestyle is estimated to provide a fillip to the market. Hepatocellular carcinomas (HCCs) account for the majority (75–90%) of primary liver cancers. A significant number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, are modifiable and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.
North America and Southern Europe have the highest incidence of mortality ratios for liver cancer. Incidence rates varied geographically, with the highest incidence rates for males recorded in Eastern Asia (31.9 per 100,000) and South-Eastern Asia (22.2 per 100,000). The highest incidence rates for females were reported in Eastern Asia (10.2 per 100,000) and Western Africa (8.1 per 100,000)
US Liver Cancer Drugs Market is poised to grow at a sustainable CAGR for the next forecast year.
To get more reports on the above market click here to Buy The Report
Global Liver Cancer Drugs Market is segmented by Drug, Type, Distribution Chanel, and region. Based on Drug, the market is segmented into Targeted Therapy, Immunotherapy, and Chemotherapy. Based on Type, the market is segmented into Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, and Others. Based on Distribution Chanel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Liver Cancer Drugs Market Analysis By Distribution Channel
Based on the distribution channel, In 2022, the segment made up of hospitals and diagnostic labs held the majority of the market. The majority of people receive their primary diagnosis and care in hospitals. Conditions such as cholangiocarcinoma, Hepatocellular Carcinoma (HCC), and others require facilities for disease management & treatment in a long-term manner.Moreover, hospitals & diagnostic laboratories provide patients with cost-effective screening products. This segment is expected to grow during the forecast period due to the availability of skilled professionals, cutting-edge techniques, sample collection, and highly sensitive data in one location.
The hospital segment will maintain its dominance thanks to rising patient numbers and prescription drug sales for treating liver cancer disorders, particularly hepatocellular carcinoma. Additionally, the growing trend among customers to frequently purchase goods from nearby pharmacies is assisting in the expansion of this market. Due to the penetration of online pharmacies in both developing and developed countries, the segment of online pharmacies is anticipated to experience a profitable CAGR during the forecast period.
To get detailed analysis on other segments, Request For Free Sample Report
North America held the dominant share with an estimated 40.37% share earned in 2022. This is owing to the presence of well-established healthcare infrastructure, coupled with an extensive reimbursement framework. Additionally, the increasing implementation of novel diagnostics, and adoption of healthcare insurance policies will further help this region continue dominance. Furthermore, due to the rising incidence of various tumor cases, supportive government organizations such as IARC, CDC, and NIH, the research & development of new testing & screening methods is also projected to help promote market growth.
Asia Pacific on the other hand, is projected to witness the highest growth rate during the forecast years. This is attributed to the significant growth of the geriatric population exposed to risk factors in developing nations. Additionally, rise in initiatives by governments & private organizations to improve access to healthcare are also promoting market growth.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Liver Cancer Drugs Market Drivers
Rise in Number of Smokers, and Alcoholics Leads to Liver Issues
Liver Cancer Drugs Market Restraints
Strict Regulatory Procedures may Challenge Growth
Request Free Customization of this report to help us to meet your business objectives.
The liver cancer therapeutics market is consolidated in nature with the presence of a handful of players. The key market players are focusing on R&D to bring innovative treatments for the treatment of liver cancer. The entry of new players may create a challenging environment for existing players. Increase in efforts such as collaboration, merger and acquisition strategies, among others are likely to help players gain a competitive edge in the overall market competition during the forecast period.
Liver Cancer Drugs Market Top Player’s Company Profile
Liver Cancer Drugs Market Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Component types team that Collects, Collates, Correlates, andAnalyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our liver cancer drug market analyses, The impact of COVID-19 on the world has been unprecedented and astounding, with positive demand shocks for liver cancer therapeutics occurring in all regions as a result of the pandemic. The market's growth and demand, which abruptly increased CAGR, will subside after the pandemic is over and the market returns to pre-epidemic levels. The large number of healthcare facilities and the developed infrastructure, after that North America used to dominate the business. Despite this, the Asia Pacific region is predicted to increase at the quickest rate due to the expansion of healthcare in developing countries. As per categorization by end-user, the hospitals and diagnostic laboratories segment dominated the market.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 3.18 Billion |
Market size value in 2032 | USD 13.64 Billion |
Growth Rate | 17.6% |
Base year | 2024 |
Forecast period | 2025-2032 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Liver Cancer Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Liver Cancer Drugs Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Liver Cancer Drugs Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Liver Cancer Drugs Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35B2174
sales@skyquestt.com
USA +1 351-333-4748